Arbutus Biopharma Cp (ABUS)

$3.06 -0.08 (-2.55%)
Market Cap 592.57M
Revenue (ttm) 18.14M
Net Income (ttm) -72.85M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 649,900
Avg Vol 936,122
Day's Range N/A - N/A
Shares Out 188.72M
Stochastic %K 2%
Beta 1.98
Analysts Strong Sell
Price Target $4.50

Company Profile

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reaw...

Industry: Biotechnology
Sector: Healthcare
Phone: 267 469 0914
Address:
701 Veterans Circle, Warminster, United States
Fachau
Fachau Aug. 26 at 9:06 PM
$ABUS no way i am selling at this tender. My money has been sitting here for years and it's time for my handsome paycheck.
0 · Reply
Heavey
Heavey Aug. 26 at 8:38 PM
$ABUS have any of us actually been contacted externally with regards to the Dutch auction? Apparently if we were to sell in this auction it would be free of brokerage fees. So we wouldn’t be selling via our own platforms. If Lindsay doesn’t reply 😉, who do we contact? FYI, 1000% NOT selling.
2 · Reply
CapitalismUSA
CapitalismUSA Aug. 26 at 8:23 PM
$ABUS If Too Few Tender (Undersubscription): If an overwhelming majority of shareholders refuse to sell within the range, the company will not reach its target volume. In this scenario, the company typically has three options: Buy Fewer Shares: Purchase only the shares tendered up to the highest price in the specified range. Raise the Price Range: Extend the offer timeline and increase the price range to attract more sellers. Cancel the Offer: Exercise the offer's conditions to cancel the buyback entirely and return all tendered shares to investors.
1 · Reply
MRenton
MRenton Aug. 26 at 8:06 PM
$ABUS Price will remain here until the auction is over Why? because of proration risk
1 · Reply
Heavey
Heavey Aug. 26 at 7:44 PM
$ABUS $5.20 is the new $4.60….. bogged.
0 · Reply
Mountainmannn
Mountainmannn Aug. 26 at 7:05 PM
$ABUS
0 · Reply
Mountainmannn
Mountainmannn Aug. 26 at 7:04 PM
$ABUS $MRNA " He said take any rug in the house!"
1 · Reply
SpaceCityKid
SpaceCityKid Aug. 26 at 6:35 PM
$ABUS Trading ABUS ought to be really exciting the next few weeks.
0 · Reply
FatedFish
FatedFish Aug. 26 at 5:12 PM
$ABUS So the tender offer is like a future sale agreement? Hasn't actually taken place yet? And will be done in the end of Sept All shares sold between 5 and 5.75 will then be taken off the market at once and the new baseline price will be the floor?
1 · Reply
DocPharm
DocPharm Aug. 26 at 4:35 PM
$ABUS waiting for a 5.15/5.16 add now 😏 This will be one hell of a support line when it moves north
1 · Reply
Latest News on ABUS
Arbutus Biopharma commences $230M modified Dutch Auction tender offer

2026-08-24T11:45:12.000Z - 2 days ago

Arbutus Biopharma commences $230M modified Dutch Auction tender offer

Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share

Aug 24, 2026, 7:30 AM EDT - 2 days ago

Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share

Arbutus Biopharma to repurchase $230M of shares through Dutch Auction

2026-08-21T11:40:40.000Z - 5 days ago

Arbutus Biopharma to repurchase $230M of shares through Dutch Auction

Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer

Aug 21, 2026, 7:30 AM EDT - 5 days ago

Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer

Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Aug 12, 2026, 7:30 AM EDT - 14 days ago

Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Arbutus Biopharma Quarterly report: Q2 2026

Aug 12, 2026, 7:00 AM EDT - 14 days ago

Arbutus Biopharma Quarterly report: Q2 2026

Arbutus Biopharma Earnings release: Q2 2026

Aug 12, 2026, 7:00 AM EDT - 14 days ago

Arbutus Biopharma Earnings release: Q2 2026

Arbutus Biopharma expects to return $230M in capital to shareholders

2026-07-16T11:50:33.000Z - 5 weeks ago

Arbutus Biopharma expects to return $230M in capital to shareholders

Arbutus initiates patent infringement actions against Pfizer, BioNTech

2026-07-16T11:45:21.000Z - 5 weeks ago

Arbutus initiates patent infringement actions against Pfizer, BioNTech

BNTX PFE ROIV

Arbutus Biopharma receives $178M settlement agreement from Moderna

2026-07-16T11:45:13.000Z - 5 weeks ago

Arbutus Biopharma receives $178M settlement agreement from Moderna

MRNA

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders

Jul 16, 2026, 7:30 AM EDT - 5 weeks ago

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 13, 2026, 7:30 AM EDT - 3 months ago

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

Arbutus Biopharma Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 3 months ago

Arbutus Biopharma Quarterly report: Q1 2026

Arbutus Biopharma Earnings release: Q1 2026

May 13, 2026, 7:00 AM EDT - 3 months ago

Arbutus Biopharma Earnings release: Q1 2026

Arbutus Biopharma granted Fast Track designation for imdusiran

2026-04-15T11:35:22.000Z - 4 months ago

Arbutus Biopharma granted Fast Track designation for imdusiran

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

Apr 15, 2026, 7:30 AM EDT - 4 months ago

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

Arbutus Biopharma Proxy statement: Proxy filing

Apr 14, 2026, 8:00 AM EDT - 4 months ago

Arbutus Biopharma Proxy statement: Proxy filing

Arbutus Biopharma Proxy statement: Proxy filing

Apr 14, 2026, 8:00 AM EDT - 4 months ago

Arbutus Biopharma Proxy statement: Proxy filing

Arbutus Biopharma price target lowered to $5.50 from $7 at Jefferies

2026-04-07T14:33:40.000Z - 5 months ago

Arbutus Biopharma price target lowered to $5.50 from $7 at Jefferies

MRNA

Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Mar 23, 2026, 7:30 AM EDT - 5 months ago

Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Arbutus Biopharma Earnings release: Q4 2025

Mar 23, 2026, 7:00 AM EDT - 5 months ago

Arbutus Biopharma Earnings release: Q4 2025

Arbutus Biopharma Annual report: Q4 2025

Mar 23, 2026, 7:00 AM EDT - 5 months ago

Arbutus Biopharma Annual report: Q4 2025

Why Is Moderna (MRNA) Stock Surging Today, 3/4/26?

2026-03-04T16:55:47.000Z - 6 months ago

Why Is Moderna (MRNA) Stock Surging Today, 3/4/26?

MRNA

Moderna resolves litigation with Arbutus, to pay up to $2.25B in settlement

2026-03-04T11:49:13.000Z - 6 months ago

Moderna resolves litigation with Arbutus, to pay up to $2.25B in settlement

MRNA ROIV

Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant

Mar 3, 2026, 4:46 PM EST - 6 months ago

Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant

MRNA

Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute

Mar 3, 2026, 4:26 PM EST - 6 months ago

Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute

MRNA ROIV

Genevant, Arbutus announce $2.25B global settlement with Moderna

2026-03-03T21:24:20.000Z - 6 months ago

Genevant, Arbutus announce $2.25B global settlement with Moderna

MRNA ROIV

Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna

Mar 3, 2026, 4:15 PM EST - 6 months ago

Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna

ROIV MRNA

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

Mar 3, 2026, 4:15 PM EST - 6 months ago

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

ROIV MRNA

Moderna Resolves Global Patent Litigation with Arbutus/Genevant

Mar 3, 2026, 4:15 PM EST - 6 months ago

Moderna Resolves Global Patent Litigation with Arbutus/Genevant

MRNA

Arbutus faces higher bar to argue infringement by Moderna, says Jefferies

2026-02-02T19:50:34.000Z - 7 months ago

Arbutus faces higher bar to argue infringement by Moderna, says Jefferies

MRNA

Moderna reverses lower after court issues memo in patent fight with Arbutus

2026-02-02T19:35:56.000Z - 7 months ago

Moderna reverses lower after court issues memo in patent fight with Arbutus

MRNA

Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 7:30 AM EST - 10 months ago

Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Arbutus Biopharma Earnings release: Q3 2025

Nov 13, 2025, 7:00 AM EST - 10 months ago

Arbutus Biopharma Earnings release: Q3 2025

Arbutus Biopharma Quarterly report: Q3 2025

Nov 13, 2025, 7:00 AM EST - 10 months ago

Arbutus Biopharma Quarterly report: Q3 2025

Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

Oct 7, 2025, 8:00 AM EDT - 11 months ago

Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

Arbutus Biopharma Earnings release: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 1 year ago

Arbutus Biopharma Earnings release: Q2 2025

Arbutus Biopharma Quarterly report: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 1 year ago

Arbutus Biopharma Quarterly report: Q2 2025

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 7:30 AM EDT - 1 year ago

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

Jun 25, 2025, 7:30 AM EDT - 1 year ago

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 7:30 AM EDT - 1 year ago

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

Arbutus Biopharma Quarterly report: Q1 2025

May 14, 2025, 7:30 AM EDT - 1 year ago

Arbutus Biopharma Quarterly report: Q1 2025

Arbutus Biopharma Earnings release: Q1 2025

May 14, 2025, 7:30 AM EDT - 1 year ago

Arbutus Biopharma Earnings release: Q1 2025

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

May 7, 2025, 2:01 AM EDT - 1 year ago

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Apr 23, 2025, 2:01 AM EDT - 1 year ago

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Arbutus Biopharma Proxy statement: Proxy Filing

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Arbutus Biopharma Proxy statement: Proxy Filing

Arbutus Biopharma Proxy statement: Proxy Filing

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Arbutus Biopharma Proxy statement: Proxy Filing

Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle

Mar 27, 2025, 7:56 AM EDT - 1 year ago

Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Mar 27, 2025, 7:30 AM EDT - 1 year ago

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Arbutus Biopharma Earnings release: Q4 2024

Mar 27, 2025, 7:30 AM EDT - 1 year ago

Arbutus Biopharma Earnings release: Q4 2024

Arbutus Biopharma Annual report: Q4 2024

Mar 27, 2025, 7:30 AM EDT - 1 year ago

Arbutus Biopharma Annual report: Q4 2024

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

Mar 3, 2025, 9:15 AM EST - 1 year ago

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

ROIV

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

Feb 25, 2025, 7:00 AM EST - 1 year ago

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

Arbutus Provides 2025 Corporate and Financial Update

Jan 13, 2025, 7:30 AM EST - 1 year ago

Arbutus Provides 2025 Corporate and Financial Update

Arbutus Biopharma Transcript: Status Update

Dec 3, 2024, 11:00 AM EST - 1 year ago

Arbutus Biopharma Transcript: Status Update

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Dec 3, 2024, 8:00 AM EST - 1 year ago

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

Nov 26, 2024, 7:30 AM EST - 1 year ago

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

Arbutus Biopharma Transcript: Jefferies London Healthcare Conference 2024

Nov 21, 2024, 7:00 AM EST - 1 year ago

Arbutus Biopharma Transcript: Jefferies London Healthcare Conference 2024

Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

Nov 15, 2024, 11:02 AM EST - 1 year ago

Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

Arbutus to Present at Jefferies London Healthcare Conference

Nov 14, 2024, 7:30 AM EST - 1 year ago

Arbutus to Present at Jefferies London Healthcare Conference

Arbutus Biopharma Earnings Call Transcript: Q3 2024

Nov 6, 2024, 8:45 AM EST - 1 year ago

Arbutus Biopharma Earnings Call Transcript: Q3 2024

Arbutus Biopharma Quarterly report: Q3 2024

Nov 6, 2024, 8:45 AM EST - 1 year ago

Arbutus Biopharma Quarterly report: Q3 2024

Arbutus Biopharma Earnings release: Q3 2024

Nov 6, 2024, 8:45 AM EST - 1 year ago

Arbutus Biopharma Earnings release: Q3 2024

Arbutus Biopharma Registration statement: Registration Filing

Nov 6, 2024, 7:00 AM EST - 1 year ago

Arbutus Biopharma Registration statement: Registration Filing

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Oct 23, 2024, 7:30 AM EDT - 2 years ago

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

Oct 15, 2024, 8:16 AM EDT - 2 years ago

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

Arbutus Biopharma Transcript: H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Oct 8, 2024, 1:30 PM EDT - 2 years ago

Arbutus Biopharma Transcript: H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Arbutus Biopharma Transcript: Baird's 2024 Global Healthcare Conference

Sep 10, 2024, 8:30 AM EDT - 2 years ago

Arbutus Biopharma Transcript: Baird's 2024 Global Healthcare Conference

Arbutus Biopharma Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 9, 2024, 8:00 AM EDT - 2 years ago

Arbutus Biopharma Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Arbutus to Participate in Two Upcoming Investor Conferences

Sep 3, 2024, 7:30 AM EDT - 2 years ago

Arbutus to Participate in Two Upcoming Investor Conferences

Arbutus Biopharma Earnings Call Transcript: Q2 2024

Aug 1, 2024, 8:45 AM EDT - 2 years ago

Arbutus Biopharma Earnings Call Transcript: Q2 2024

Arbutus Biopharma Quarterly report: Q2 2024

Aug 1, 2024, 8:45 AM EDT - 2 years ago

Arbutus Biopharma Quarterly report: Q2 2024

Arbutus Biopharma Earnings release: Q2 2024

Aug 1, 2024, 8:45 AM EDT - 2 years ago

Arbutus Biopharma Earnings release: Q2 2024

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 1, 2024, 7:30 AM EDT - 2 years ago

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Jul 18, 2024, 7:30 AM EDT - 2 years ago

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

Jun 6, 2024, 11:15 AM EDT - 2 years ago

Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

Arbutus Biopharma Transcript: Jefferies 2024 Global Healthcare Conference

Jun 5, 2024, 9:30 AM EDT - 2 years ago

Arbutus Biopharma Transcript: Jefferies 2024 Global Healthcare Conference

Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

Jun 5, 2024, 2:30 AM EDT - 2 years ago

Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

Arbutus Distributors Ltd. News Release

Jun 3, 2024, 9:50 AM EDT - 2 years ago

Arbutus Distributors Ltd. News Release

Arbutus to Participate in Jefferies Global Healthcare Conference

May 29, 2024, 7:30 AM EDT - 2 years ago

Arbutus to Participate in Jefferies Global Healthcare Conference

Arbutus to Present Imdusiran Data at EASL Congress 2024

May 22, 2024, 2:00 AM EDT - 2 years ago

Arbutus to Present Imdusiran Data at EASL Congress 2024

Arbutus Biopharma Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 20, 2024, 3:30 PM EDT - 2 years ago

Arbutus Biopharma Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

May 17, 2024, 9:00 AM EDT - 2 years ago

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

Arbutus Biopharma Transcript: The Citizens JMP Life Sciences Conference

May 14, 2024, 9:30 AM EDT - 2 years ago

Arbutus Biopharma Transcript: The Citizens JMP Life Sciences Conference

Arbutus Biopharma Earnings Call Transcript: Q1 2024

May 2, 2024, 8:45 AM EDT - 2 years ago

Arbutus Biopharma Earnings Call Transcript: Q1 2024

Arbutus Biopharma Quarterly report: Q1 2024

May 2, 2024, 8:45 AM EDT - 2 years ago

Arbutus Biopharma Quarterly report: Q1 2024

Arbutus Biopharma Earnings release: Q1 2024

May 2, 2024, 8:45 AM EDT - 2 years ago

Arbutus Biopharma Earnings release: Q1 2024

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 2, 2024, 7:30 AM EDT - 2 years ago

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

May 2, 2024, 7:25 AM EDT - 2 years ago

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

Apr 18, 2024, 7:30 AM EDT - 2 years ago

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

Arbutus Biopharma Proxy statement: Proxy Filing

Apr 10, 2024, 8:00 AM EDT - 2 years ago

Arbutus Biopharma Proxy statement: Proxy Filing

Arbutus Biopharma Proxy statement: Proxy Filing

Apr 10, 2024, 8:00 AM EDT - 2 years ago

Arbutus Biopharma Proxy statement: Proxy Filing

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

Apr 4, 2024, 8:30 AM EDT - 2 years ago

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

Arbutus Biopharma Transcript: Barclays 26th Annual Global Healthcare Conference 2024

Mar 12, 2024, 2:05 PM EDT - 2 years ago

Arbutus Biopharma Transcript: Barclays 26th Annual Global Healthcare Conference 2024

Arbutus Biopharma Earnings Call Transcript: Q4 2023

Feb 29, 2024, 8:45 AM EST - 2 years ago

Arbutus Biopharma Earnings Call Transcript: Q4 2023

Arbutus Biopharma Annual report: Q4 2023

Feb 29, 2024, 8:45 AM EST - 2 years ago

Arbutus Biopharma Annual report: Q4 2023

Arbutus Biopharma Earnings release: Q4 2023

Feb 29, 2024, 8:45 AM EST - 2 years ago

Arbutus Biopharma Earnings release: Q4 2023

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Feb 29, 2024, 7:30 AM EST - 2 years ago

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

Feb 15, 2024, 7:30 AM EST - 2 years ago

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

Jan 8, 2024, 7:30 AM EST - 2 years ago

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

Arbutus Biopharma Transcript: 14th Annual Jefferies London Healthcare Conference 2023

Nov 15, 2023, 6:30 AM EST - 3 years ago

Arbutus Biopharma Transcript: 14th Annual Jefferies London Healthcare Conference 2023

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

Nov 9, 2023, 4:01 PM EST - 3 years ago

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

Arbutus Biopharma Slides: Corporate Presentation

Nov 9, 2023, 7:00 AM EST - 3 years ago

Arbutus Biopharma Slides: Corporate Presentation

Arbutus Biopharma Earnings Call Transcript: Q3 2023

Nov 7, 2023, 8:45 AM EST - 3 years ago

Arbutus Biopharma Earnings Call Transcript: Q3 2023

Arbutus Biopharma Quarterly report: Q3 2023

Nov 7, 2023, 8:45 AM EST - 3 years ago

Arbutus Biopharma Quarterly report: Q3 2023

Arbutus Biopharma Earnings release: Q3 2023

Nov 7, 2023, 8:45 AM EST - 3 years ago

Arbutus Biopharma Earnings release: Q3 2023

Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 7, 2023, 7:30 AM EST - 3 years ago

Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Arbutus Announces CEO, William Collier, to Retire December 31, 2023

Nov 7, 2023, 7:15 AM EST - 3 years ago

Arbutus Announces CEO, William Collier, to Retire December 31, 2023

Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update

Oct 24, 2023, 7:30 AM EDT - 3 years ago

Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update

Fachau
Fachau Aug. 26 at 9:06 PM
$ABUS no way i am selling at this tender. My money has been sitting here for years and it's time for my handsome paycheck.
0 · Reply
Heavey
Heavey Aug. 26 at 8:38 PM
$ABUS have any of us actually been contacted externally with regards to the Dutch auction? Apparently if we were to sell in this auction it would be free of brokerage fees. So we wouldn’t be selling via our own platforms. If Lindsay doesn’t reply 😉, who do we contact? FYI, 1000% NOT selling.
2 · Reply
CapitalismUSA
CapitalismUSA Aug. 26 at 8:23 PM
$ABUS If Too Few Tender (Undersubscription): If an overwhelming majority of shareholders refuse to sell within the range, the company will not reach its target volume. In this scenario, the company typically has three options: Buy Fewer Shares: Purchase only the shares tendered up to the highest price in the specified range. Raise the Price Range: Extend the offer timeline and increase the price range to attract more sellers. Cancel the Offer: Exercise the offer's conditions to cancel the buyback entirely and return all tendered shares to investors.
1 · Reply
MRenton
MRenton Aug. 26 at 8:06 PM
$ABUS Price will remain here until the auction is over Why? because of proration risk
1 · Reply
Heavey
Heavey Aug. 26 at 7:44 PM
$ABUS $5.20 is the new $4.60….. bogged.
0 · Reply
Mountainmannn
Mountainmannn Aug. 26 at 7:05 PM
$ABUS
0 · Reply
Mountainmannn
Mountainmannn Aug. 26 at 7:04 PM
$ABUS $MRNA " He said take any rug in the house!"
1 · Reply
SpaceCityKid
SpaceCityKid Aug. 26 at 6:35 PM
$ABUS Trading ABUS ought to be really exciting the next few weeks.
0 · Reply
FatedFish
FatedFish Aug. 26 at 5:12 PM
$ABUS So the tender offer is like a future sale agreement? Hasn't actually taken place yet? And will be done in the end of Sept All shares sold between 5 and 5.75 will then be taken off the market at once and the new baseline price will be the floor?
1 · Reply
DocPharm
DocPharm Aug. 26 at 4:35 PM
$ABUS waiting for a 5.15/5.16 add now 😏 This will be one hell of a support line when it moves north
1 · Reply
sheepmanct
sheepmanct Aug. 26 at 3:28 PM
$ABUS for those following/invested in ROIV https://investor.roivant.com/news-releases/news-release-details/jama-dermatology-publishes-skin-specific-outcomes-phase-3-valor/
3 · Reply
SpaceCityKid
SpaceCityKid Aug. 26 at 2:45 PM
$ABUS As of 8/14, the Short Interest dropped 8.80% to 18,456,085 shares. A good sign, but the end of the month #, which will be reported in about 2 weeks, will be more telling.
0 · Reply
Alfalcon
Alfalcon Aug. 26 at 1:59 PM
$ABUS can we consider officially leaving penny stock land? Provided we stay pinned above threshold?
1 · Reply
GreenDreamz
GreenDreamz Aug. 26 at 1:14 PM
$ABUS When 10+?
1 · Reply
NoBSPls
NoBSPls Aug. 26 at 12:52 PM
$ABUS After 40+ years of trading, this is my first experience with a Dutch Auction. I’m guessing they are finding enough tenders at $5.20 or less so no need to go up to $5.75? For my part, I’m buying at these levels anticipating a floor around $5.00 and several potential catalysts to take it higher once the auction concludes. I’ve been in this one for 6 years. Will patience finally pay off?🙏
4 · Reply
Heavey
Heavey Aug. 26 at 11:00 AM
$ABUS https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abus/arbutus-biopharma/news/is-arbutus-biopharma-abus-fully-valued-following-its-230-mil/amp
0 · Reply
Grtgooglymoogly
Grtgooglymoogly Aug. 25 at 8:36 PM
$ABUS Short Interest DOWN -8.8 percent.....(1.8 million shares)
0 · Reply
Kempo73
Kempo73 Aug. 25 at 6:33 PM
$ABUS Just got this update. ABUS litigation update — August 24, 2026 The Federal Circuit granted an accelerated schedule in Moderna’s Section 1498 appeal and plans to hear oral arguments in November 2026. The appeal is case No. 26-1581. Law360 report⁠ Why it matters: This could bring forward a ruling governing Moderna’s additional contingent payment of up to $1.3 billion to Arbutus/Genevant. A qualifying Federal Circuit decision in their favor would require payment within 90 days, although later appeals could still reverse the result and require repayment. Moderna SEC filing⁠ The scheduling order does not change the merits or probability of either side prevailing. No new material TPST development was identified.
1 · Reply
MRVivke
MRVivke Aug. 25 at 6:28 PM
$ABUS if you've never seen a float get locked up in real time just keep watching. No time frame but this is exactly whats happening.
0 · Reply
DocPharm
DocPharm Aug. 25 at 6:03 PM
$ABUS great to see - pressure has been turned up
1 · Reply
deaccord
deaccord Aug. 25 at 5:54 PM
$ABUS Bought all that I could this. A. M. Safe bet
0 · Reply
buffalosoldiertwo
buffalosoldiertwo Aug. 25 at 5:06 PM
$ABUS looks like they are just gonna peg us till Sep 29.
2 · Reply